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Abstract
Background: Parkinson's disease (PD) is the most common movement disorder. While neuronal deposition of α-
synuclein serves as a pathological hallmark of PD and Dementia with Lewy Bodies, α-synuclein-positive protein 
aggregates are also present in astrocytes. The pathological consequence of astrocytic accumulation of α-synuclein, 
however, is unclear.
Results: Here we show that PD-related A53T mutant α-synuclein, when selectively expressed in astrocytes, induced 
rapidly progressed paralysis in mice. Increasing accumulation of α-synuclein aggregates was found in presymptomatic 
and symptomatic mouse brains and correlated with the expansion of reactive astrogliosis. The normal function of 
astrocytes was compromised as evidenced by cerebral microhemorrhage and down-regulation of astrocytic glutamate 
transporters, which also led to increased inflammatory responses and microglial activation. Interestingly, the activation 
of microglia was mainly detected in the midbrain, brainstem and spinal cord, where a significant loss of dopaminergic 
and motor neurons was observed. Consistent with the activation of microglia, the expression level of cyclooxygenase 1 
(COX-1) was significantly up-regulated in the brain of symptomatic mice and in cultured microglia treated with 
conditioned medium derived from astrocytes over-expressing A53T α-synuclein. Consequently, the suppression of 
COX-1 activities extended the survival of mutant mice, suggesting that excess inflammatory responses elicited by 
reactive astrocytes may contribute to the degeneration of neurons.
Conclusions: Our findings demonstrate a critical involvement of astrocytic α-synuclein in initiating the non-cell 
autonomous killing of neurons, suggesting the viability of reactive astrocytes and microglia as potential therapeutic 
targets for PD and other neurodegenerative diseases.
Background
α-synuclein (α-syn) is a major component of Lewy bodies
(LB) and Lewy neurites (LN) appearing in the postmor-
tem brain of Parkinson's disease (PD) and other synucle-
inopathies [1,2]. Genetic mutations in α-syn, including
point mutations (A53T, A30P and E46K) and multiplica-
tions have been linked to familial PD and Dementia with
LB [3-7]. Although the precise function of α-syn remains
elusive, overwhelming evidence indicates that malfunc-
tion of α-syn, especially the aggregation of misfolded α-
syn, plays an important role in the process of neurode-
generation [5,8].
Neuronal expression of either human wild-type or PD-
related mutant α-syn induces neurodegeneration associ-
ated with pathological accumulations of α-syn and reac-
tive astrogliosis [9-13]. In addition, α-syn-containing
inclusion bodies are present in oligodendrocytes of mul-
tiple system atrophy (MSA) [14]. Transgenic mice over-
expressing wild-type α-syn in oligodendrocytes display
severe neurological alterations and neurodegeneration
[15,16]. Previous studies also reveal that α-syn-containing
inclusion bodies present in astrocytes of sporadic PD [17-
19] and over-expression of wild-type or C-terminally
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truncated α-syn in U373 astrocytoma cells induces apop-
totic death of astroglial cells [20]. However, whether the
astrocytic expression of PD-related A53T α-syn contrib-
utes to neurodegeneration is unknown [21].
Here we generated a new line of α-syn inducible trans-
genic mice in which the PD-related A53T α-syn was
selectively expressed by astrocytes. Interestingly, the
mutant mice developed rapidly progressed paralysis,
likely resulting from widespread astrocytosis, severe
microglial activation, and especially midbrain dopamin-
ergic and spinal cord motor neuron degeneration. These
results demonstrate that α-syn-mediated cytotoxicity to
astrocytes is critical for inducing the non-cell autono-
mous degeneration of neurons, suggesting that the main-
tenance of normal function of astrocytes is important in
ameliorating the progression of neurodegeneration in PD
and other neurodegenerative diseases.
Results
Generation of human α-synuclein inducible transgenic 
mice that selectively express exogenous α-synuclein in 
astrocytes
α-syn  is most abundant in neurons [22]. However, the
expression of α-syn in astrocytes has not been rigorously
examined. Here we prepared the astrocytic and neuronal
cell cultures from postnatal day 1 pups and compared the
expression of α-syn in these cells. Consistent with previ-
ous findings [22], α-syn was highly expressed in neuronal
cultures (Fig. 1A). Interestingly, a lower level expression
of α-syn was consistently detected in astrocytes (Fig. 1A).
To reveal the potential contribution of astrocytic
expression of α-syn in the pathogenesis of PD, we gener-
ated new lines of α-syn inducible transgenic mice that
selectively expressed the human wild-type (WT) or PD-
related A53T α-syn in astrocytes. As outlined in Fig. 1B,
we crossbred the human glial fibrillary acidic protein
(GFAP) promoter-controlled tetracycline transactivator
(GFAP-tTA) transgenic mice [23] with the tetracycline
operator (tetO)-regulated α-syn  transgenic mice (tetO-
WT or tetO-A53T) to generate the GFAP-tTA/tetO-WT
(WT) and GFAP-tTA/tetO-A53T  double transgenic
(A53T) mice. The expression of exogenous α-syn in the
double transgenic mice was demonstrated by Western
blot using an antibody specifically against human α-syn.
We have obtained one WT and two A53T lines of trans-
genic mice (Fig. 1C). Since most of studies focused on the
A53T-E2 line, we refer this line as A53T  mice in later
description. The A53T transgenic mice displayed signifi-
cant elevation of α-syn expression throughout the CNS,
including olfactory bulb, cerebral cortex, striatum, mid-
brain, hippocampus, cerebellum, brainstem and spinal
cord (Fig. 1D). Using an α-syn antibody that recognizes
both mouse and human α-syn, Western blot analysis
revealed about 10-fold increase of α-syn expression in the
brain of A53T mice as compared to non-transgenic (nTg)
littermate controls (see Additional file 1A). Moreover, at
t h e  c e l l u l a r  l e v e l ,  t h e  e x p r e s s i o n  o f  A 5 3 T  α - s y n  w a s
restricted to GFAP-positive astrocytes as demonstrated
by co-staining of human α-syn with GFAP but not other
cell type markers in the brain sections of A53T mice (Figs.
1E-H; Additional file 1B-D).
The A53T transgenic mice developed an early onset rapidly 
progressed movement disability
To investigate whether over-expression of A53T α-syn in
astrocytes caused any behavioral abnormalities, we moni-
tored the body weight and examined the spontaneous
locomotor activities and motor coordination of A53T
mice. The A53T mice were viable but appeared smaller
and weighted significantly less compared to age-matched
nTg, as well as GFAP-tTA and tetO-A53T single trans-
genic mice at one and two months of age (see Additional
file 2A-B). The spontaneous locomotor activities of A53T
mice measured by the Open-field test were progressively
declined from one month to two months of age compared
to control mice (Fig. 2A; Additional file 2C-D). The grip
strength of A53T mice was also significantly reduced in
both fore and hind limbs at two months of age (Fig. 2B).
The motor coordination of two-month old A53T mice
seemed, however, not affected in the Rotarod test (see
Additional file 2E). After two and a half months of age,
the progression of movement disability of A53T mice was
greatly accelerated. One of the four limbs paralyzed with
the average age of onset at 71.6 ± 2.0 days (Fig. 2C, Addi-
tional files 3, Additional file 4). The paralysis quickly
spread to the remaining limbs, and the affected mice
experienced difficulties in eating and drinking after
showing paralysis in two or more limbs. As a result, the
body weight of symptomatic mice continued to drop dur-
ing the disease progression (see Additional file 2F), and
eventually, the animals died with the average lifespan at
90.4 ± 2.9 days (Fig. 2D, Additional file 5). The pene-
trance of paralysis was 100% in A53T mice.
Previous studies also indicated that GFAP is expressed
in neuronal precursor cells during development [24,25].
To assess the impact of developmental expression of
A53T α-syn on the neurological dysfunction, a cohort of
A53T mice were administered with doxycycline (DOX), a
tetracycline derivative, to block the expression of A53T
α-syn from embryonic stages to postnatal day 21 (P21).
The DOX-exposed A53T mice behaved normally at one
and two months of age (see Additional file 6). However,
two months after removal of DOX, 43% of these mice
started to lose body weight and displayed less spontane-
ous locomotor activities (see Additional file 6). All of
these DOX-treated A53T mice eventually progressed to
complete paralysis with an average age of onset at 102.1 ±
2.8 days and average lifespan at 110.0 ± 3.8 days. TheseGu et al. Molecular Brain 2010, 3:12
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data suggest that the paralysis developed by A53T mice is
not dependent on the developmental expression of A53T
α-syn.
Astrocytic expression of A53T α-synuclein induced 
widespread astrogliosis
To reveal the cause of neurological dysfunction, we
checked whether A53T α-syn affected astrocytes in the
brain. Brain sections of both asymptomatic (A53T 1M)
and symptomatic mice (A53T*) were examined for GFAP
staining (Fig. 3). The number of GFAP-positive astrocytes
was dramatically increased in the gray matter of cerebral
cortex (Figs. 3B-C), striatum (Figs. 3B-C), brainstem
(Figs. 3E-F), spinal cord (Figs. 3H-I), midbrain (Figs. 3K-
L), and other brain areas of A53T mice as compared to
Figure 1 Astrocytic expression of human α-synuclein in mice. (A). Western blot analysis of endogenous α-syn expression in primary cultured cor-
tical neurons and astrocytes. Protein extracts (8 μg) from cultured cortical neurons and astrocytes were immunoblotted using antibodies against hu-
man/mouse α-syn (C20), β III-tubulin (neuronal marker), and GFAP (astrocyte maker). β-actin serves as the loading control. (B) A schematic outline of 
the "tet-off" system for astrocytic expression of α-syn in mice. The tetracycline operator-controlled human α-syn responder mice (tetO-α-syn) were 
crossed with GFAP-tTA activator mice to generate GFAP-tTA/tetO-α-syn double transgenic (A53T) mice, which selectively expressed exogenous human 
α-syn in astrocytes. (C) Western blot analysis of human α-syn expression in transgenic mice. One wild-type (WT) and two A53T lines (A8 and E2) of trans-
genic mice were obtained. The expression of exogenous human α-syn was detected by a human α-syn-specific antibody, α-syn (211). (D) The expres-
sion pattern of human α-syn in the brain of A53T (E2 line) transgenic mice revealed by Western blot using both human-specific and human/mouse α-
syn antibodies. BS: brainstem, OB: olfactory bulb, Ctx: cortex, ST: striatum, Hip: hippocampus, MB: midbrain, CB: cerebellum; SC: spinal cord. (E-H) Rep-
resentative images show human α-syn (red) and GFAP (green) co-staining in the striatum of A53T mice. The α-syn immunoreactivity is restricted to 
GFAP-expressing astrocytes. Scale bar: 20 μm.Gu et al. Molecular Brain 2010, 3:12
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age-matched  nTg  mice (Figs. 3A, D, G and 3J). The
increase of GFAP expression was also confirmed by
quantitative RT-PCR and Western blot analyses in which
the level of GFAP expression was further elevated in the
symptomatic mice (see Additional file 7). Moreover, the
soma size of GFAP-positive astrocytes was also signifi-
cantly increased in the brainstem, spinal cord, and mid-
brain of symptomatic A53T mice (nTg, 27.8 ± 5.7 μm2;
A53T*, 132.0 ± 34.9 μm2; p = 0.0051) (Figs. 3A'-C', D'-F',
G'-I' and 3J'-L'). Taken together, these results demonstrate
that exogenous expression of human A53T α-syn in astro-
cytes induced severe astrogliosis in mice.
Astrocytic expression of A53T α-synuclein disrupted the 
normal function of astrocytes
Astrocyte plays an important role in maintenance the
homeostasis of extracellular environment of neurons
[26]. The processes of astrocyte end-feet encircle the
endothelial cell of blood vessels for maintenance of
blood-brain barrier (BBB) and withdrawal of nutrients
from the blood [27,28]. The astrocyte-endothelial cell
interaction plays a major role in regulating brain water
and electrolyte metabolism under both normal and path-
ological conditions [27]. In search for the signs of BBB
damage in the brain of symptomatic A53T  mice, we
examined the expression and subcellular distribution of
Figure 2 Early-onset neurological dysfunction and shortened lifespan of A53T mice. (A) Open-field tests reveal a significant decline of sponta-
neous ambulatory activities in A53T mice as compared to littermate controls at 1 and 2 months of age. **p < 0.01, ***p < 0.001. (B) Both fore and hind 
limb grip strength of A53T mice are impaired compared to littermate controls at 2 months of age. *p < 0.05, **p < 0.01. (C) Line graph reveals the onset 
of paralysis observed in A53T mice (n = 20). The average age of onset was 71.6 ± 2.0 days. (D) Line graph depicts the survival rate of A53T mice (n = 7). 
The average lifespan of the A53T mice was 90.4 ± 2.9 days.Gu et al. Molecular Brain 2010, 3:12
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aquaporin 4, glucose transporter 1 (Glut1) and von Wille-
brand factor (vWF) in astrocyte and vascular endothelial
cells. As shown in the brainstem of nTg mice, aquaporin 4
was normally confined to the end-foot of astrocytes that
outlined the blood vessels in the brain (Figs. 4A, C and
4 E ) .  I n  t h e  b r a i n s t e m  a n d  s p i n a l  c o r d  o f  s y m p t o m a t i c
A53T mice; however, aquaporin 4 was redistributed to
the soma and proximal processes of astrocytes (Figs. 4B,
D and 4F). The redistribution of aquaporin 4 to the soma
of astrocyte has been shown before to impair the shield-
ing of end-foot around blood vessels [29]. In addition,
abnormal accumulation of Glut1 and vWF in the vascular
endothelial cell was observed at the brainstem and spinal
cord of symptomatic A53T mice (Figs. 4G-J), indicating
the dysfunction of vascular endothelial cells. Together
these data indicate that astrocytic expression A53T α-syn
may cause damage to BBB. In support of this notion, focal
deposition of immunoglobulin (Ig) G was observed in the
brainstem of A53T  symptomatic mice (Fig. 4L). More-
over, Prussian blue staining from symptomatic mice iden-
tified deposits of hemosiderin, a hemoglobin derivative,
in the brainstem (Fig. 4N), suggesting the occurrence of
microhemorrhage in these mice.
Astrocytes also express excitatory amino acid trans-
porters, which are responsible for the majority of gluta-
mate uptake in the brain and its dysfunction has been
associated with multiple psychiatric and neurological dis-
orders [30]. Here we found that the expression of excit-
atory amino acid transporter 1 and 2 (GLAST, GLT1) was
significantly decreased in asymptomatic and symptom-
atic A53T mice (Figs. 4O-P), indicating that excitotoxicity
may occur in A53T mice.
Astrocytic expression of A53T α-synuclein induced 
activation of microglia in the CNS
Astrocytes are active players in cerebral innate immunity
[31]. To investigate whether reactive astrocyte in symp-
tomatic A53T mice triggered inflammatory response, we
examined whether microglia, the immune defense cell in
the CNS, were activated. Progressive activation of micro-
Figure 3 More GFAP-enriched and hypertrophic astrocytes in A53T mice. (A-L') Representative images show GFAP staining (green) in the cere-
bral cortex-striatum (A-C'), brainstem (D-F'), spinal cord (G-I'), and substantia nigra pars compacta (SNpc) (J-L') of nTg mice (2.5-month old) and A53T 
mice at asymptomatic (1-month old, A53T 1M) and symptomatic (A53T*) stages. Hypertrophy of astrocytes is shown in the brainstem (F'), spinal cord 
(I'), and SNpc (L') of symptomatic A53T mice. The SNpc dopaminergic neurons were revealed by tyrosine hydroxylase (TH) staining (J-L, red). Scale bar: 
200 μm (A-C, D-F, G-I), 50 μm (J-L), and 20 μm (A'-C', D'-F', G'-I', J'-L').Gu et al. Molecular Brain 2010, 3:12
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Figure 4 Dysfunction of astrocytes in A53T mice. (A-F) Representative images show the co-staining of GFAP (C, D, green) and aquaporin 4 (A, B, 
red) in the brainstem of symptomatic A53T mice (B, D, F) and nTg littermates (A, C, E). Aquaporin 4 was redistributed into the cell body and proximal 
processes of astrocytes in the symptomatic A53T mice (B, D, F). Scale bar: 20 μm. (G-H) Representative images show glucose transporter 1 (Glut-1) 
staining in the epithelia cell of the symptomatic A53T mice (H) as well as age-matched nTg controls (G). The expression of Glut-1 was up-regulated in 
the A53T mice. Scale bar: 50 μm. (I-J) Double labeling of GFAP (green) and von Willebrand factor (vWF, red) in the brainstem of symptomatic A53T mice 
(J) and nTg littermates (I). The expression of vWF was elevated in A53T mice. Scale bar: 50 μm. (K-L) Representative images show double staining for 
IgG (green, arrowhead) and vWF (red) in the brainstem of symptomatic A53T mice (L) but not in the nTg littermate controls (K). Scale bar: 50 μm. (M-
N) Representative images show the Prussian blue staining (nuclei were counterstained with fast red) in the brain stem of symptomatic A53T (N) and 
control mice (M). Scale bar: 20 μm. (O) Western blot analysis of the expression levels of excitatory amino acid transporter 1 and 2 (GLAST and GLT1) 
in the brainstem of A53T and control nTg mice. (P) Bar graph compares the levels of GLT1 and GLAST proteins in nTg, asymptomatic (A53T 1M) and 
symptomatic A53T mice (n = 3 per genotype). *p < 0.05, **p < 0.01.Gu et al. Molecular Brain 2010, 3:12
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Figure 5 Activation of microglia in A53T mice. (A-C) Representative images show Iba1 staining in cortex (Ctx), brainstem (BS) and substance nigra 
pars compacta (SNc) sections derived from A53T and nTg littermate control mice. Scale bars: 50 μm (A), 200 μm (B-C). (D-E), Quantitative measure-
ment of the microglia (Iba1 positive cells) and microglia clusters in the cortex, substantia nigra pars compacta and brainstem (n = 3 per genotype). 
**p < 0.01, ***p < 0.001, compared with nTg; ##p < 0.01, compared with cortex.Gu et al. Molecular Brain 2010, 3:12
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glia was observed in the brain of A53T mice (Figs. 5A-C)
as evidenced by enlarged soma and by the appearance of
microglia clusters (Figs. 5A-C). Clusters of activated
microglia with large, amoeboid shape and fewer branches
were spotted firstly in the peduncle of cerebellum at
asymptomatic stage, and later in the brainstem (Figs. 5B
and 5D-E) and midbrain (Figs. 5C and 5D-E) at symptom-
a t i c  s t a g e .  A l t h o u g h  a s t r o c y t o s i s  w a s  o b s e r v e d  i n  t h e
forebrain regions (Fig. 3), interestingly, no obvious activa-
tion of microglia was observed in the cortical areas (Figs.
5A and 5D-E). Consistent with the morphology change of
the microglia, the expression of Iba1 was dramatically up-
regulated in the A53T mice as evidenced by quantitative
RT-PCR and western blot analysis (see Additional file 7).
More interestingly, clusters of activated microglia were
found adjacent to spinal motor neurons and dopaminer-
gic neurons in substantial nigra pars compacta (SNpc)
(see Additional file 8). These data indicate that activated
microglia may attack neurons in the spinal cord and SNpc
and lead to neurodegeneration.
Astrocytic expression of A53T α-synuclein caused 
neurodegeneration
To examine whether neuronal loss occurred in the brain
of symptomatic A53T mice, unbiased stereological analy-
sis was employed to estimate the remained neurons in the
cortex, striatum, SNpc, and spinal cord. While the num-
bers of tyrosine hydroxylase (TH)-positive dopaminergic
neurons in SNpc and ventral tegmental area (VTA) were
not altered in the A53T mice at 1 month of age (see Addi-
tional file 9), they were decreased by 60.5% in SNpc and
by 26.1% in VTA of symptomatic A53T mice as compared
with age-matched nTg littermates (Figs. 6A, C). Similarly,
the numbers of motor neurons were significantly reduced
in both cervical and lumber spinal cord of symptomatic
A53T mice compared to control mice (Figs. 6B, D). In
contrast, the number of neurons in the cerebral cortex
and striatum area symptomatic A53T  mice remained
unchanged (see Additional file 9). Taken together, signifi-
cant neuronal loss was detected in the midbrain and spi-
nal cord of A53T symptomatic mice, which may underlie
the movement disability developed in these animals. In
addition, the close correlation of regional distribution
between the occurrence of neurodegeneration and
microglial activation indicate that activated microglia
may play an important role in triggering the loss of neu-
ron.
Microglia-mediated inflammatory responses were involved 
in the neurodegeneration of A53T mice
Increasing studies demonstrate the involvement of
inflammation in the degeneration of neurons [32]. Since
inflammation is often in accompany with increased
expression of cytokines, such as tumor necrosis factor-α
(TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6),
we quantified the expression of TNF-α, IL-1β, and IL-6 in
the cortex and brainstem of A53T mice at both presymp-
tomatic and symptomatic stages. At the presymptomatic
stage when little activated microglia were observed, there
was no significant alteration of TNF-α, IL-1β, and IL-6
expression in the cerebral cortex and brainstem of A53T
mice (Figs. 7A-C). By contrast, at the symptomatic stage,
a dramatic increase of TNF-α, IL-1β, and IL-6 expression
was observed in the brainstem but not in the cerebral cor-
tex of A53T mice (Figs. 7A-C), which is closely correlated
with the presence of activated microglia (Figure 5). These
results indicate that the increase production of cytokines
is mainly from activated microglia. Consistently, the
expression level of cyclooxygenase-1 (COX-1), which
expression is restricted to microglia, was also up-regu-
Figure 6 Neuron loss occurred in the midbrain and the spinal 
cord of symptomatic A53T mice. (A) Representative images show TH 
and NeuN double staining in the SNpc area of symptomatic A53T mice 
and age-matched nTg littermates. Scale bars: 100 μm. (B) Representa-
tive images show NeuN staining in the ventral horn of lumbar spinal 
cord of symptomatic A53T mice and age-matched nTg littermates. 
Scale bar: 100 μm. (C) Bar graph depicts the numbers of TH-positive 
dopaminergic neurons in the SNpc and ventral tegmental area (VTA) 
of symptomatic A53T mice and nTg littermates (n = 3) estimated by un-
biased stereological methods. *p < 0.05, **p < 0.01. (D) Bar graph re-
veals the numbers of motor neurons remained in the cervical and 
lumbar spinal cord of the symptomatic A53T mice and age-matched 
nTg littermates (n = 3). *p < 0.05.Gu et al. Molecular Brain 2010, 3:12
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lated in the brainstem of symptomatic A53T mice; while
the expression level of neuron-enriched COX-2 was not
affected (Figs. 7D-E).
To further demonstrate the origin of cytokines from
activated microglia, we compared the expression of TNF-
α, IL-1β, and IL-6 in primary cultured astrocytes from the
brainstem of symptomatic A53T mice and age-matched
littermate controls. No significant increase of TNF-α, IL-
1β, and IL-6 expression was observed in cultured astro-
cytes from A53T mouse brainstem compared to control
cultures (Fig. 7G), indicating a limited contribution of
astrocytes in the direct production of cytokines. In con-
trast, the expression level of IL-1β and COX-1 was signif-
icantly up-regulated in cultured microglia treated with
conditioned medium derived from cultured astrocytes of
A53T mouse brainstem (Fig. 7H). These results indicate
that substances released from A53T α-syn-expressing
astrocytes may induce the production of proinflamma-
tory cytokines from microglia.
COX-1 is the key and rate-limiting enzyme in conver-
sion of arachidonic acid to prostaglandins (PGs) and
plays an important role in the neuroinflammatory pro-
cess [33]. To evaluate the contribution of COX-1 activity
in the progression of paralysis in A53T mice, we treated
Figure 7 Increase of inflammatory response in A53T mice. (A-E), Quantitative PCR array analysis of the expression of cytokines in the tissues of the 
brainstem (BS) and cerebral cortex (Ctx) of A53T mice at asymptomatic (1 M) and symptomatic (2.5) stages (n = 3 per genotype and per stage). *p < 
0.05, **p < 0.01. (F), Survival curve shows the lifespan of A53T mice treated with COX-1 inhibitor, SC-560 (n = 5) or 40% vehicle, DMSO (n = 4). Log-rank 
test, *p < 0.05. (G), Quantitative PCR array analysis of the expression of cytokines in cultured astrocytes from the brainstem of A53T or nTg mice (n = 3 
per genotype). *p < 0.05, **p < 0.01, ***p < 0.001. (H), Quantitative PCR array analysis of the expression of cytokines in the cultured primary microglia 
treated with conditioned medium from cultured astrocytes of the brainstem of A53T or nTg mice (n = 3 per genotype). *p < 0.05.Gu et al. Molecular Brain 2010, 3:12
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presymptomatic 2-month old A53T mice with SC-560 (30
mg/kg, i.p.), a selective inhibitor of COX-1 [34] once a day
for 7 days. Compared to that of vehicle-treated mice, the
lifespan of SC-560-treated A53T mice was significantly
extended (Fig. 7F, p = 0.035), suggesting that microglia-
mediated inflammatory responses directly contribute to
the neurodegeneration in A53T mice.
The accumulation of aggregated and truncated forms of α-
synuclein in A53T mice
The aggregated or truncated forms of α-syn has been
indicated in initiating the downstream pathogenic events
of neurodegeneration [35]. We decided to examine the
correlation between each form of α-syn and the progres-
sion of paralysis in A53T mice. We first checked the pres-
ence of α-syn aggregates in the brain, which appeared as
α-syn-positive high molecular weight bands in Western
blot analysis and resistant to Triton-X100 (TX) extraction
in tissue fractionation studies. The aggregation of α-syn
was significantly increased in the brain of symptomatic
A53T mice compared with nTg controls and asymptom-
atic mice (Fig. 8A). Moreover, in agreement with the
above neuropathological studies, the ratios of TX-insolu-
ble α-syn were significantly higher in the brainstem as
compared to the cerebral cortex of A53T mice (Figs. 8B-
E). A similar phenomenon was also observed for trun-
cated form of α-syn, which was selectively up-regulated
in the brainstem of symptomatic A53T mice (Figs. 8F-G).
Taken together, these data suggest that the aggregated
and truncated forms of α-syn may impair the normal
function of astrocytes and initiate the downstream patho-
genic cascades leading to the loss of neurons in A53T
mice.
Discussion
Although α-syn is less abundant in glial cells [36], α-syn-
containing inclusion bodies are present in astrocytes of
postmortem PD brains [17-19]. By using a "tet-off" induc-
ible transgenic approach, we selectively expressed PD-
related A53T α-syn in astrocytes to investigate the patho-
logical consequence of astrocytic expression and aggrega-
tion of α-syn in vivo. We show here that the presence of
excess A53T α-syn in astrocyte caused severe astroglio-
sis, which disrupted the normal function of astrocytes
critical for maintaining the integrity of blood-brain bar-
rier and homeostasis of extracellular glutamate. The
A53T α-syn induced astrogliosis also led to inflammation
and microglial activation, particularly in the midbrain,
brainstem and spinal cord. We further revealed a signifi-
cant loss of dopaminergic neurons in the midbrain and
motor neurons in the spinal cord of symptomatic mice,
which may underlie the paralysis phenotypes developed
by these mutant mice. In addition, COX-1-mediated
inflammatory pathways may contribute to the neurode-
generation as evidenced by the beneficial effect of COX-1
inhibitor in extending the lifespan of A53T mice. Finally,
the more severe pathological abnormalities shown in the
brainstem of A53T mice were correlated with the more
a b u n d a n t  a c c u m u l a t i o n  o f  a g g r e g a t e d  a s  w e l l  a s  t r u n -
cated forms of α-syn in this region. Together, our findings
demonstrate that astrocytic expression of PD-related
A53T α-synuclein causes non-cell autonomous killing of
neurons implicated in PD and motor neuron diseases,
suggesting that reactive astrocytes may serve as a poten-
tial therapeutic target for treatment of these movement
disorders.
I t is rather surprising to find that over -expression of
A53T α-syn  in astrocytes induced more robust loss of
midbrain dopaminergic neuron than other published
A53T α-syn transgenic mice in which the expression of
mutant α-syn is under the control of neuronal promoters
[10,12,37,38]. Astrocytes may have to keep a lower level
expression of α-syn for their normal functions. Therefore,
over-expression of α-syn in astrocytes may cause more
severe phenotypes compared to that in neurons. It is also
possible that astrocyte is less able to detoxify the excess
α-syn because of its lower level of cathepsin D which is
recently proved to effectively degrade α-syn [39-41]. To
address the importance of expression level of exogenous
A53T α-syn  in astrocytes in determining the onset of
behavioral and neuropathological phenotypes in A53T
mice, we also examined the behavioral and neuropatho-
logical phenotypes of A53T-A8 mice (the low expression
line). Compared to the early onset paralysis exhibited in
A53T-E2  m i c e  ( t h e  h i g h  e x p r e s s i o n  l i n e ) ,  n o  o b v i o u s
behavior abnormalities were observed in A53T-A8 mice
up to 12 months of age (data now shown). However,
astrogliosis and modest microglial activation were
detected in the brainstem and SNpc area of A53T-A8
mice at 12 months of age (see Additional file 10). The
milder phenotypes of A53T-A8 mice clearly indicate that
the expression level of exogenous α-syn determines the
onset and severity of observed behavioral and pathologi-
cal abnormalities in these mutant mice. This observation
is also consistent with the earlier genetic studies that mul-
tiplications of α-syn  gene in patients cause early-onset
familial PD [3,4].
Astrocytic expression of A53T α-syn appears to affect
multiple functions of astrocytes, resulting in decreased
glutamate transporter expression, and disruption of
brain-blood barrier. Astrogliosis happened throughout
the brain and spinal cord at both asymptomatic and
symptomatic stages. However, the activation of microglia
was relatively confined to the midbrain, brainstem and
spinal cord of symptomatic mice. It remains to determine
why microglia responds differently to the dysfunction of
astrocytes in different regions of the brain. Alternatively,
under the stress of excess A53T α-syn, astrocytes mayGu et al. Molecular Brain 2010, 3:12
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react differently in the brainstem compared to the cere-
bral cortex. In line with this notion, more aggregated and
truncated forms of α-syn were detected in the brainstem
than in the cortex. Astrocytes in the brainstem are per-
haps less capable to remove the toxic α-syn species from
the cells and are thereby more vulnerable to α-syn-medi-
ated cytotoxicity, which may generate greater damage to
surrounding cells, including enhanced activation of
microglia and loss of neurons.
The degeneration of midbrain dopaminergic neurons
and spinal motor neurons may account for the paralysis
of symptomatic A53T mice. Although the precise molec-
ular mechanism of this rather selective loss of dopamin-
ergic and motor neurons remains to be elucidated, it is
Figure 8 Increased accumulation of aggregated and truncated α-synuclein in A53T mice. (A) Western blot analysis shows high molecular 
weight (HMW) α-syn-positive bands in brainstem homogenates of A53T mice as compared to nTg controls. β-actin serves as loading control. (B-C) 
Western blot analysis shows the presence of HMW α-syn was more abundant in the brainstem than the cerebral cortex of A53T mice at different time 
points (B). Bar graph shows the ratio of HMW-α-syn/monomeric (Mono)-α-syn in the cortex (Ctx) and brainstem (BS) of A53T mice during the progres-
sion of paralysis (C). ***p < 0.0001. (D-E) Western blot analysis shows the level of α-syn in sequentially detergent-extracted cerebral cortex and brain-
stem homogenates of nTg and A53T mice (D). Bar graph reveals the ratio of total, TX-soluble, and TX-insoluble α-syn in the Ctx and BS of symptomatic 
A53T mice (E). Signal intensities of α-syn were normalized by β-actin. *p < 0.05. (F-G) Western bolt analysis shows the level of C-terminal truncated α-
syn (pointed by arrows) using an antibody that specifically recognizes N-terminal 1-100 amino acids of α-syn (F). Bar graph depicts the ratio of trun-
cated α-syn against total α-syn in the Ctx and BS of symptomatic A53T mice (G). *p < 0.05.Gu et al. Molecular Brain 2010, 3:12
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possible that the survival of these neurons is more depen-
d e n t  o n  t h e  n o r m a l  f u n c t i o n  o f  a s t r o c y t e s  t h a n  o t h e r
types of neurons. For instance, both midbrain dopamin-
ergic neurons and motor neurons are preferentially vul-
nerable to the dysfunction of glutamate transporters [42],
which were also down-regulated in our A53T mice. Inter-
estingly, microglial activation was mainly detected in
regions where neurodegeneration happened in A53T
mice. The activated microglia is known to promote neu-
rodegeneration by producing proinflammatory or poten-
tially neurotoxic effectors, including IL-1β, NO, or
reactive oxygen species (ROS) [43-45]. Microglia presents
the most highest density in SNpc [46]. Thus the loss of
SNpc dopaminergic neurons in A53T mice may attribute
to the activation of nearby microglia. This hypothesis is
in line with recent reports that lipopolysaccharide, an
activator of microglia, causes SNpc dopaminergic neuron
degeneration in vivo [47-49]. Nonetheless, it will be inter-
esting to determine which factor is more important in the
degeneration of dopaminergic neurons in A53T mice.
Our findings firmly support the non-cell autonomous
toxicity which is well documented in neurodegenerative
disease including PD, amyotrophic lateral sclerosis (ALS),
Huntington's disease (HD) and Alzheimer's disease (AD)
[50]. α-syn expression in oligodendrocytes causes neu-
ronal degeneration [16], while astrocytes expressing
mutant Cu/Zn superoxide dismutase (SOD1) drive dis-
ease progression [51]. Recent study shows that mutant
huntingtin in glial cells induces HD neurological symp-
toms even when it is not overexpressed [52], strongly
indicating the critical role of mutant huntingtin in glial
cells. Given the non-cell autonomous toxicity caused by
glial cells in neurodegenerative disease, glial cells in par-
ticular reactive astrocytes may serve as a potential thera-
peutic target for treatment of these movement disorders
Conclusions
Our studies from this new line of A53T α-syn transgenic
mice not only provide strong evidences for the critical
involvement of astrocytes in the pathogenesis of PD and
motor neuron diseases, but also provide a very useful in
vivo system to test novel therapeutics for preventing the
loss of dopaminergic and motor neurons.
Methods
Mice
To generate human A53T α-synuclein (α-syn) inducible
transgenic mice, a DNA fragment containing human
wild-type (WT) or A53T α-syn  coding sequence was
inserted into a tetracycline operator-regulated gene
expression vector (tet-O) to generate the WT or A53T
inducible expression construct. The insert was then puri-
fied and microinjected into fertilized oocytes derived
from C57BL6/J mice. One WT and two A53T founders
were obtained, which were used to cross with GFAP-tTA
mice [23] to generate GFAP-tTA/tetO-α-syn  double
transgenic mice. The mice were housed in a pathogen-
free climate-controlled facility with ad libitum access to
regular diet and water. Genotypes were determined by
PCR analysis of tail DNA extracted by DirectPCR
Reagents (VIAGEN Biotech, CA). PCR primers for geno-
typing GFAP-tTA mice are: tTA-F (5'CCCTTGGAATT-
GACGAGTAC GGTG3') and MP1R (5'TGGTGTA
TGAGCGGCGGCGACGGCAG3'); and for genotyping
tetO-α-syn mice are: PrpEx2-F (5'TACTGCTCCATTT
TGCGTGA3') and SNCA-R (5'TCCAGAATTCCTTCC
TGTGG3'). All mouse work follows the guidelines
approved by the Institutional Animal Care and Use Com-
mittees of the National Institute of Child Health and
Human Development.
Behavioral test
Rotarod test: as described previously [53], mice were
placed onto a rotating rod with auto acceleration from 0
rpm to 40 rpm in 2 min (San Diego Instruments, San
Diego, CA). The length of time the mouse stayed on the
rotating rod was recorded.
Open-field test: as described previously [53], the ambu-
latory, fine and rearing activities of mice were measured
by the Flex-Field activity system (San Diego Instruments,
CA). Flex-Field software was used to trace and quantify
mouse movement in the unit as the number of beam
breaks per 30 min.
Grip strength measurement: as described previously
[54], mice were allowed to use their forepaws or hind
paws to pull or compress a triangular bar attached to a
digital force gauge (Ametek, Largo, FL) set up to record
the maximal pulling or compressing force. Five measure-
ments were taken for each animal during each test.
Histology and Immunohistochemical Analyses
As described previously [54], mice were perfused via car-
diac infusion with 4% paraformaldehyde in cold PBS. To
obtain frozen sections, brain and spinal cord tissues were
removed and submerged in 30% sucrose for 24 h and sec-
tioned at 40 μm thickness with cryostat (Leica CM1950).
For paraffin sections, sections at 8 μm thickness were
obtained according to standard procedure. Antibodies
specific to glial fibrillary acidic protein (GFAP) (1:1000,
Sigma-Aldrich USA, St. Louis, MO), ionized calcium
binding adaptor molecule-1 (Iba1, 1:1000, Wako Chemi-
cals USA, Richmond, VA), tyrosine hydroxylase (TH,
1:1000, Pel-Freez Biologicals, Rogers, AR), α-synuclein
(C20 &211, 1:1000, Santa Cruz Biotech, Santa Cruz, CA),
Aquaporin 4 (1:500, Chemicon International, Inc USA,
CA), glucose transporter 1 (1:500, Chemicon), von Wille-
brand Factor (1:500, Dako USA, Carpinteria, CA), iNOSGu et al. Molecular Brain 2010, 3:12
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(1:500, Sgima), SMI32 (Sternberger Monoclonal, Luther-
ville, MD), NeuN (1:1000, Chemicon) were used as sug-
gested by manufacturers. Alexa 488 or Alex 568-
conjugated secondary antibody (1:1000, Invitrogen) was
used to visualize the staining, and Topro3 (1:1000, Invit-
rogen) was used for counterstaining the nuclei. Fluores-
cence images were captured using a laser scanning
confocal microscope (LSM 510; Zeiss, Thornwood, NJ).
The Images of 100 × objective (bar = 20 μM) were pre-
sented as a single optic layer after acquired in z-series
stack scans at 0.8 μM intervals from individual field. The
numbers of microglia and microglia cluster in the images
taken from 25 × objective (368 μm × 368 μm) were
counted.
Stereology
According to stereotaxic coordinates of mouse brains
(3rd edition, Keith B.J. Franklin and George Paxinos), a
series of coronal sections across the striatum (9 sections
by every 10th section, Bregma -2.06-1.54 mm), SNpc (7
sections by every 4th section, Bregma -2.70- -3.82 mm), as
well as cervical (approximate T1-T6) and lumbar spinal
cord (approximate L1-L5, 10 sections by every 12th sec-
tion) were stained with NeuN plus TH and NeuN, respec-
tively, and visualized using the Vectastain ABC kit
(Vector Laboratories, Burlingame, CA). The number of
NeuN or TH-positive cells was assessed using Stereo
Investigator 8, an unbiased stereological procedure with
an optical fractionator (MicroBrightField Inc, Williston,
VT). The sampling scheme was designed to have coeffi-
cient of error (CE) less than 10% in order to get reliable
results. All stereological analyses were performed under
the 100 × objective of a Zeiss Axio microscope (Imager
A1).
Primary cell cultures
Primary cortical neuron cultures were conducted as
described previously [55] by using postnatal day 1 pups.
For cortical astrocyte and microglia cultures [56], the dis-
persed cells were collected by centrifugation and plated
on 75 cm2 flasks in DMEM supplemented with 10% fetal
bovine serum (FBS). The cells were pre-incubated at 37°C
in a humidified atmosphere of air/5% CO2  and the
medium was changed first 24 h later and on alternate 3-
days thereafter. After a pre-culture period of 8-11 days
the cellular debris, microglia were lifted from astrocytes
layer by shaking the culture flasks at 190 rpm for 3 h at
30°C. The cells attached to the flask were passed and
grown in six-well plates for 3 days until harvest for astro-
cytes culture. The cells floating in the medium were col-
lected by centrifuge and plated on 6-well plates in DMEM
supplemented with 10% FBS for microglial culture. After
24 h incubation, the medium of microglial cultures was
switched to conditioned medium from cultured astro-
cytes.
Tissue fractionation
As previously described (Xian et al., in press), brain tis-
sues (cerebral cortex, brainstem) were weighed and
homogenized with 10 volumes of sucrose buffer (0.32 M
sucrose, 1 mM NaHCO3, 1 mM MgCl2, and 0.5 mM
CaCl2, plus protease and phosphatase inhibitor cocktails).
Lysates were centrifuged at 1, 000 g for 10 min to separate
supernatant (S1) and pellet (P1). Protein concentrations
i n  S 1  w e r e  m e a s u r e d  b y  B C A  ( P i e r c e  B i o t e c h n o l o g y ,
Rockford, IL). S1 contains total α-synuclein protein, rep-
resenting the sucrose fraction. An aliquot of S1 was
diluted in the same volume of Triton extraction buffer
(2% Triton X-100, 20 mM HEPES, plus protease and
phosphatase inhibitor cocktails), homogenized by sonica-
tion, and centrifuged at 20, 000 × g for 30 min to obtain
the Triton X-100-soluble (TX-sol) supernatant (S2) and
Triton X-100-insoluble (TX-insol) pellet (P2). P2 was
washed 4 times by 1% Triton X-100 buffer and centri-
fuged at 20, 000 × g for 10 min. The pellet fraction was
further extracted in 2% SDS buffer (2% SDS, 20 mM
HEPES, plus protease and phosphatase inhibitor cock-
tails) by sonication and centrifuged at 20, 800 × g for 5
min. The supernatant (S3) were present as Triton X-100-
insoluble (TX-insol) or SDS-soluble fraction.
Western Blot
Proteins were size-fractioned by 4-12% NuPage BisTris-
polyacrylamide gel electrophoresis (Invitrogen) using
MOPS running buffer (Invitrogen), and transferred to
polyvinylidene difluoride (PVDF) or Nitrocellulose mem-
branes. Antibodies specific to human/mouse α-synuclein
(SynC20 recognizing the C terminal of both human and
mouse α-synuclein, 1:1000, Santa Cruz; Syn-1 recogniz-
ing both human and mouse α-synuclein encoding amino
acids 1-100, 1:1000, BD Biosciences, San Diego) [35] and
β-actin (1:5000, Sigma) as loading control were used in
this study. Horseradish peroxidase conjugated secondary
antibodies were from Jackson ImmunoResearch. Signals
were visualized by enhanced chemiluminescence devel-
opment (Pierce, Rockford, IL) and quantified by imageJ
software (NIH).
COX-1 inhibition
For COX-1 inhibitor treatment, mutant mice and control
littermates at 2 months of age were administrated with
SC-560 (30 mg/kg; Cayman Chemical, Ann Arbor, MI,
USA) or vehicle (40% dimethyl sulfoxide in 0.1 M phos-
phate buffer, pH 7.4) through intraperitoneal (IP) injec-
tion once a day for 7 days [34].Gu et al. Molecular Brain 2010, 3:12
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Quantitative real-time PCR array
RNA was harvested using Qiagen RNeasy mini kit and
converted into first-strand cDNA using RT2 First Strand
Kit (SuperArray Bioscience Corporation). Quantitative
real-time PCR was performed using an ABI Prism
7900HT Fast Detection System (Applied Biosystems).
Statistical Analysis
Statistical analysis was performed using the Graphpad
Prism 5 (Graphpad Software Inc. La Jolla, CA). Data are
presented as Means ± SEM. Statistical significances were
determined by comparing means of different groups
using t-test or ANOVA followed by Post Hoc Tukey HSD
test, and presented as *p < 0.05, **p < 0.01, ***p < 0.001.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
XLG and HC designed the experiments and wrote the manuscript. XLG, CXL,
CSX and LS performed the experiments. XL provided some materials. All
authors have read and approved the final manuscript.
Acknowledgements
This work was supported by the intramural research programs of National Insti-
tute on Aging at the National Institutes of Health (H.C., Z01-AG000959-05). We 
thank Dr. Xiao-Jiang Li for helpful suggestions. We thank the NIH Fellows Edito-
rial Board for manuscript editing.
Author Details
Units of Transgenesis, Laboratory of Neurogenetics, National Institute on 
Aging, National Institute of Health, Bethesda, Maryland 20892, USA
Additional file 1 PD-related human A53T α-synuclein was selectively 
expressed in the astrocytes of A53T transgenic mice. (A) Western blot 
analysis reveals the expression level of exogenous α-syn in asymptomatic 
A53T mice. Protein extracts (5 μg) from the hippocampus were diluted by 1, 
2, 4, 8, 16, 32 and 64-fold and equal volume of diluted samples was sub-
jected to Western blot with a human/mouse specific α-syn antibody, α-syn 
(C20). (B-E) To determine the expression pattern of tTA under the GFAP pro-
moter, GFAP-tTA mice were crossbred with tetO-HIST1H2BJ/GFP to yield 
GFAP-tTA/tetO-GFP mice. HIST1H2BJ/GFP is located in the nucleus. Brain sec-
tions of GFAP-tTA/tetO-GFP mice were stained with NeuN (neuronal marker, 
B), Iba1 (microglia marker, C), OSP (oligodentrocyte specific protein, D), and 
GFAP (marker for astrocytes, E). Scale bars: 20 μm.
Additional file 2 Progressive reduction of body weight and spontane-
ous locomotor activities in A53T mice. (A) Representative photos of A53T 
mice and age-matched littermate controls under anesthetized condition. 
(B) Bar graph shows the body weight of A53T mice and control littermates 
at 1 and 2 months of age. ***p < 0.001. (C-D) Bar graphs depict the fine 
movement (C) and rearing activities (D) of A53T mice and control litter-
mates at 1 and 2 months of age. *p < 0.05, ***p < 0.001. (E) Bar graph dis-
plays results from Rotarod test of A53T mice and littermate controls. Latency 
to fall was recorded at 1 and 2 months of age. (F) Body weight curves of 
A53T mice and littermates from 1 to 3 months of age. The body weight of 
A53T mice and littermates was measured twice a week. Concurrent with the 
abnormal motor behavior symptoms, the body weight of A53T mice was 
dropped continuously. Once the mice were unable to feed themselves 
(usually, body weight was dropped by 30%), they were sacrificed for histol-
ogy and biochemistry study.
Additional file 3 The TreadScan Gait Analysis System (Clever Sys, Res-
ton, VA) was used to record the gait information of A53T mice. Each 
mouse was placed on the belt of treadmill unit. The movement of each 
paw was recorded with the treadmill running at 17 cm/s, 5 cm/s and 2 cm/
s, respectively [54]. A representative control nTg mouse was running on the 
treadmill with the speed set at 17 cm/s. The later part of movie was 
replayed four times slower than the first part to better visualize the place-
ment of each paw on the belt.
Additional file 4 Symptomatic A53T mice were only able to run at the 
speed of 5 cm/s. The first mouse showed paralysis in both forelimbs. The 
second mouse displayed paralysis in the left forelimb and in both 
hindlimbs.
Additional file 5 A53T mice developed rapid progression of paralysis 
in four limbs. This mouse was able to run at the speed of 5 cm/s on post-
natal day 65 (P65), but 2 cm/s on P70. The right forelimb started to show 
paralysis on P71 and then the left forelimb was affected on P73.
Additional file 6 Behavior analysis of A53T mice treated with doxycy-
cline (DOX) from embryonic stages to postnatal day 21 (P21). (A) Dia-
gram outlines the treatment of A53T mice with DOX. DOX-containing 
mouse feed (200 mg/kg, Bioserv, Frenchtown, NJ) was provided to breed-
ing pairs and young pups till the pups were weaned at postnatal day 21. 
The new weanlings were then switched to regular feed. (B) Dot plot shows 
the change of body weight of A53T mice and littermate controls after the 
stop of DOX treatment at P21. (C-E) Dot plots show the results of Open-
field test of A53T and control mice after the stop of DOX treatment at P21. 
The spontaneous ambulatory (C), fine movement (D), and rearing activities 
(E) were quantified. (F) Dot plot depicts the performance of A53T and con-
trol mice on Rotarod test after the stop of DOX-treatment at P21. (G) Line 
graph shows the onset of paralysis of A53T mice after the stop of DOX-treat-
ment at P21.
Additional file 7 Increase of GFAP and Iba1 expression in A53T mice. 
(A-B) Bar graph shows quantitative RT-PCR analysis of Gfap and Iba1 tran-
scripts expressed in the brainstem and cortex of A53T mice and age-
matched GFAP-tTA mice (n = 3 per genotype). BS, brainstem; Ctx, cortex; 1 
M, 1 month of age; 2.5 M, 2.5 months of age; A53T*, symptomatic A53T 
mice. *p < 0.05, and ***p < 0.001. (C) Western blots analysis of GFAP and 
Iba1 protein expression in the brainstem of A53T mice and littermate con-
trols. (D-E) Bar graphs show the quantification GFAP (D) and Iba1 (E) expres-
sion in the brainstem, spinal cord, and cerebral cortex (n = 3 per genotype) 
of A53T and control mice. *p < 0.05, **p < 0.01 and ***p < 0.001.
Additional file 8 Activated microglia surrounded dopaminergic and 
spinal motor neurons. (A-F) Representative images show double immun-
ofluorescent labeling of Iba1 (green) with TH (red) and SMI32 (red) in the 
SNpc (A-C) and spinal cord (SC) (D-F) of symptomatic A53T mice. Scale bar: 
20 μm.
Additional file 9 Quantification of cortical and striatal neurons 
remained in symptomatic A53T mice. (A), Bar graph depicts the numbers 
of TH-positive dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) and ventral tegmentum area (VTA) in nTg and A53T mice at 1 month 
of age. N = 3 per genotype.(B), Bar graph depicts the numbers of NeuN-
positive neurons in the cerebral cortex and striatum of symptomatic A53T 
mice and age-matched nTg littermates estimated by unbiased stereological 
methods. N = 3 per genotype.
Additional file 10 Reactive astrocytes in the brainstem and substan-
tia nigra pars compacta of A53T lower expresser mice (A53T-A8). (A, C, 
E) Representative images of GFAP (red) and Iba1 (green) staining show mild 
astrocytosis in the brainstem and SNpc but not in the cerebral cortex of 12-
month old A53T-A8 mice compared to littermate nTg mice. (B, D, F) High 
magnification views of (A, C, E) reveal the morphology of astrocyte and 
microglia in control nTg and A53T mice at 12 month of age. Scale bars: 50 
μm(A, C, E); 20 μm (B, D, F).
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